Global Epidemiology and Antimicrobial Resistance of Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Gram-Negative Clinical Isolates: A Review
- PMID: 40732206
- PMCID: PMC12300886
- DOI: 10.3390/microorganisms13071697
Global Epidemiology and Antimicrobial Resistance of Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Gram-Negative Clinical Isolates: A Review
Abstract
Klebsiella pneumoniae carbapenemases (KPCs) are a group of class A β-lactamases of Gram-negative bacteria leading to difficult-to-treat infections. We evaluated the global epidemiology of KPC-producing Gram-negative clinical isolates. A systematic search of six databases (Cochrane Library, Embase, Google Scholar, PubMed, Scopus, and Web of Science) was conducted. Extracted data were tabulated and evaluated. After screening 1993 articles, 119 were included in the study. The included studies originated from Asia (n = 49), Europe (n = 29), North America (n = 14), South America (n = 11), and Africa (n = 3); 13 studies were multicontinental. The most commonly reported KPC-producing species were Klebsiella pneumoniae (96 studies) and Escherichia coli (52 studies), followed by Enterobacter cloacae (31), Citrobacter spp. (24), Klebsiella oxytoca (23), Serratia spp. (15), Enterobacter spp. (15), Acinetobacter baumannii complex (13), Providencia spp. (11), Morganella spp. (11), Klebsiella aerogenes (9), Pseudomonas aeruginosa (8), Raoultella spp. (8), Proteus spp. (8), and Enterobacter aerogenes (6). Among the studies with specific blaKPC gene detection, 52/57 (91%) reported the isolation of blaKPC-2 and 26/57 (46%) reported blaKPC-3. The antimicrobial resistance of the studied KPC-producing isolates was the lowest for ceftazidime-avibactam (0-4%). Resistance to polymyxins, tigecycline, and trimethoprim-sulfamethoxazole in the evaluated studies was 4-80%, 0-73%, and 5.6-100%, respectively. Conclusions: The findings presented in this work indicate that KPC-producing Gram-negative bacteria have spread globally across all continents. Implementing proper infection control measures, antimicrobial stewardship programs, and enhanced surveillance is crucial.
Keywords: Gram-negative; Klebsiella pneumoniae carbapenemase (KPC); global dissemination; global epidemiology; β-lactamase.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Characterization of a blaKPC-3-carrying plasmid in a clinical isolate of Klebsiella pneumoniae belonging to the emerging successful clone ST147.Microbiol Spectr. 2025 Jul;13(7):e0233824. doi: 10.1128/spectrum.02338-24. Epub 2025 May 23. Microbiol Spectr. 2025. PMID: 40407340 Free PMC article.
-
High transconjugation efficiency of fusion plasmid pNDM_KPC in carbapenem-resistant Citrobacter freundii and its formation driven by IS26-mediated integration.Microbiol Spectr. 2025 Aug 14:e0090525. doi: 10.1128/spectrum.00905-25. Online ahead of print. Microbiol Spectr. 2025. PMID: 40810515
-
Aztreonam-avibactam resistance rates and resistance mechanisms of NDM and NDM/OXA48-like dual-carbapenemase-producing Enterobacterales in Singapore.Pathology. 2025 Jun 19:S0031-3025(25)00205-3. doi: 10.1016/j.pathol.2025.04.010. Online ahead of print. Pathology. 2025. PMID: 40653437
-
Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports.Ann Clin Microbiol Antimicrob. 2012 Dec 13;11:32. doi: 10.1186/1476-0711-11-32. Ann Clin Microbiol Antimicrob. 2012. PMID: 23234297 Free PMC article.
-
In vitro antimicrobial activity and clinical use of trimethoprim-sulfamethoxazole for infections due to KPC-producing Gram-negative pathogens: a review.Eur J Clin Microbiol Infect Dis. 2025 Aug 14. doi: 10.1007/s10096-025-05236-z. Online ahead of print. Eur J Clin Microbiol Infect Dis. 2025. PMID: 40810969 Review.
References
-
- Lim C., Hantrakun V., Klaytong P., Rangsiwutisak C., Tangwangvivat R., Phiancharoen C., Doung-ngern P., Kripattanapong S., Hinjoy S., Yingyong T., et al. Frequency and Mortality Rate Following Antimicrobial-Resistant Bloodstream Infections in Tertiary-Care Hospitals Compared with Secondary-Care Hospitals. PLoS ONE. 2024;19:e0303132. doi: 10.1371/journal.pone.0303132. - DOI - PMC - PubMed
-
- Naghavi M., Vollset S.E., Ikuta K.S., Swetschinski L.R., Gray A.P., Wool E.E., Aguilar G.R., Mestrovic T., Smith G., Han C., et al. Global Burden of Bacterial Antimicrobial Resistance 1990–2021: A Systematic Analysis with Forecasts to 2050. Lancet. 2024;404:1199–1226. doi: 10.1016/S0140-6736(24)01867-1. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous